“The best way is to be open and honest with the patient with regard to the challenges that we are facing, the options that we have, and come together with a shared decision when possible, within the limitations that we are all facing.” In the future, not have platinum, then there will be no shared decision,” O’Malley said. Right now, we still have shared decisions. Many of these come down to shared decisions. ![]() The chemotherapy shortages have also led to difficult discussions with patients to determine the best treatment approach, given the current climate of shortages across the United States. He added that regular consultation occurs between departments that rely on platinum-based chemotherapy as a backbone of treatment, allowing leaders discuss supply management and treatment strategies. He also noted non–platinum-based regimens have been considered for patients if platinum-based chemotherapy is not associated with a survival advantage. “After that, depending on the supply-at our institution, we have more cisplatin than carboplatin- where there is an alternative regimen in which cisplatin has been shown to be equally efficacious.” We also try to prioritize patients who are being treated on clinical to maintain the integrity of that research when possible,” O’Malley said in an interview with OncLive. "We've had to come up with prioritization with regard to which patients we treat we're prioritizing patients who are curative-intent first-line therapy. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the Ohio State University Comprehensive Cancer Center – James, said his institution has implemented strategies to navigate the current treatment landscape. 4,5Īs a result of these shortages, David M. 2,3 The shortages for both agents have been attributed to manufacturing delays and increase in demand. Both drugs remain in shortage, according to the regulatory agency. The survey followed alerts from the FDA regarding shortages of cisplatin, which was first reported on February 10, 2023, and carboplatin, which was reported on April 28, 2023. We need to work together to improve the current situation and prevent it from happening again in the future.” “We were relieved by survey results that show patients are still able to get life-saving care, but it comes at a burden to our overtaxed medical facilities. Carlson, MD, chief executive officer of NCCN, stated in a news release. We are hearing from oncologists and pharmacists across the country who have to scramble to find appropriate alternatives for treating their patients with cancer right now,” Robert W. ![]() However, none have been met with outright denials. The need to reobtain prior authorization from modified treatment plans led to treatment delays at 16% of institutions. Additionally, 20% of surveyed institutions said they could continue this prescription for some but not all patients. However, only 64% of centers said they were able to keep all patients receiving carboplatin on their current regimen. ![]() In polled results gathered from 27 NCCN member institutions between May 23 and 31, 2023, the survey showed that 100% of cancer centers were still able to treat patients who need cisplatin without any delays or claim denials. A survey conducted by the National Comprehensive Cancer Network (NCCN) Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |